Follow The Filings

TNDM Tandem Diabetes Care

Tandem Diabetes Care earnings company data as of 8:02 PM ET 10/22

Limited consensus data for this ticker (thin coverage or data-plan limits). Dates may be company-announced rather than sell-side consensus. Calendar and recent prints remain the primary lens when available.

Scheduled

1 period, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 5 Nov EPS — — —
Rev — — —

Insider trades

Open-market buys and sales by TNDM's executives, directors and 10% owners in the last 12 months, from their Form 4s

All TNDM insider trades
  • None no insider bought on the open market
  • None no sales outside a trading plan
  • $4,356 sold by 1 insider under 10b5-1 plans
  1. Mark David Novara EVP & Chief Commercial Officer
    Planned sale
    $4,310 187 shares at $23.05 0.5% of stake
    Traded Mar 17 Filed Mar 18
    ↗
  2. Mark David Novara EVP & Chief Commercial Officer
    Planned sale
    $46 2 shares at $22.81 <0.1% of stake
    Traded Mar 5 Filed Mar 9
    ↗

Also filed in the last 12 months, not counted as buying or selling: 77 option exercises, 69 share withholdings for taxes, 11 stock grants, 2 gifts, and 2 other transactions.

SEC filings

Recent issuer filings from EDGAR, 6 shown.

Filed Form Detail Links
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
8-K 3.03,5.02,5.07,9.01 Filing Doc
8-K 5.02 Filing Doc
10-Q Filing Doc

Source: SEC EDGAR submissions, updated 3 days ago. All on EDGAR

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.